维普中文期刊产品整合服务
146篇 您的检索式:作者名="Senju"
    题名 作者 年代 出处 被引量
1Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C显示文摘AIM: To investigate the factors other than fibrosis stage correlating with acoustic radiation force impulse(ARFI) elastograpy in chronic hepatitis C. METHODS: ARFI elastograpy was performed in 108 consecutive patients with chronic hepatitis C who underwent a liver biopsy. The proportion of fibrosis area in the biopsy specimens was measured by computerassisted morphometric image analysis. RESULTS: ARFI correlated significantly with fibrosis stage(β = 0.1865, P < 0.0001) and hyaluronic acid levels(β = 0.0008, P = 0.0039) in all patients by multiple regression analysis. Fibrosis area correlated significantly with ARFI by Spearman's rank correlation test but not by multiple regression analysis. ARFI correlated significantly with body mass index(BMI)(β =-0.0334, P = 0.0001) in F 0 or F 1, with γ-glutamyltranspeptidase levels(β = 0.0048, P = 0.0012) in F 2, and with fibrosis stage(β = 0.2921, P = 0.0044) and hyaluronic acid levels(β = 0.0012, P = 0.0025) in F 3 or F 4. The ARFI cutoff value was 1.28 m/s for F ≥ 2, 1.44 m/s for F ≥ 3, and 1.73 m/s for F 4. CONCLUSION: ARFI correlated with fibrosis stage and hyaluronic acid but not with inflammation. ARFI was affected by BMI, γ-glutamyltranspeptidase, and hyaluronic acid in each fibrosis stage.Toru Nishikawa Senju Hashimoto Naoto Kawabe Masao Harata Yoshifumi Nitta Michihito Murao Takuji Nakano Yuko Mizuno Hiroaki Shimazaki Toshiki Kan Kazunori Nakaoka Yuka Takagawa Masashi Ohki Naohiro Ichino Keisuke Osakabe Kentaro Yoshioka 2014World Journal of Gastroenterology2014,20,5:7
2Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma显示文摘AIM:To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma(HCC).METHODS:A total of 46 patients with Barcelona Clinic Liver Cancer stage C who received sorafenib for more than 30 d at the Iizuka Hospital from June 2009 to December 2012 were enrolled in this study.Multivariate and univariate analyses were performed to evaluate the associations of hepatic function according to Child-Pugh grade,location and size of the largest tumor and adverse events of sorafenib treatment,such as hand-foot syndrome(HFS),hypertension,diarrhea,and alopecia,with the efficacy of treatment,as measured by overall survival(OS)and time to progression(TTP).RESULTS:Patients included 39 men and 7 women whose ages ranged from 48 to 85 years(70.6±9.6years).HCC was classified according to etiology as follows:hepatitis C virus(n=26),hepatitis B virus(n=9),and other(n=11).Liver function in patients was categorized as Child-Pugh grade A(n=30)or B(n=16).Tumors were categorized by size[<5 cm(n=33)or>5 cm(n=13)]and the location of the largest tumor was used to categorize patients with intrahepatic(n=28)or extrahepatic(n=18)HCC.HFS,hypertension,diarrhea,and alopecia were present in22(47.8%),19(41.3%),15(32.6%)and 7 patients(15.2%),respectively.The median OS of all patients was 373 d and the median TTP was 112 d.The etiology of HCC did not correlate with the median OS and TPP.The median OS of patients with tumors<5 cm was significantly longer than those with larger tumors(496 vs 245 d;HR=0.19,95%CI:0.07-0.48;P<0.01).According to the results of a multivariate analysis,the size of the largest tumor affected OS(HR=0.22,95%CI:0.08-0.59;P<0.01).The median TTP was significantly longer in patients with extrahepatic compared to intrahepatic major HCC(224 vs 98 d;HR=0.32;95%CI:0.14-0.67;P<0.01).The median TTP of patients with HFS was significantly longer than those without it(195 d vs 83 d;HR=0.41,95%CI:0.20-0.82;P<0.05),and the median TTP was significantly longer in patients with hypertension(195 d vs84 d;HR=0.43,95%CI:0.21-0.84;P<0.05).According to the results of the multivariate analysis,extrahepatic major HCC(HR=0.36,P<0.01)and HFS(HR=0.44,P<0.05)prolonged TTP.CONCLUSION:Extrahepatic major HCC and HFS are associated with prolonged TTP and are useful indicators for judging the efficacy of sorafenib treatment.Masayoshi Yada Akihide Masumoto Kenta Motomura Hirotaka Tajiri Yusuke Morita Hideo Suzuki Takeshi Senju Toshimasa Koyanagi 2014World Journal of Gastroenterology2014,20,35:7
3A new index for non-invasive assessment of liver fibrosis显示文摘AIM:To construct and evaluate a new non-invasive fibrosis index for assessment of the stage of liver f ibrosis. METHODS:A new f ibrosis index (Fibro-Stiffness index) was developed in 165 of 285 patients with chronic hepatitis C, and was validated in the other 120 patients where liver biopsy was performed. Its usefulness was compared with liver stiffness (LS) measured by FibroScan, the aminotransferase-to-platelet ratio index, the Forns index and the FibroIndex. RESULTS: The Fibro-Stiffness index consists of LS,platelet count and prothrombin time. The values of the Fibro-Stiffness index differed signif icantly between neighboring f ibrosis stages except F0-F1. The area under the receiver operating characteristics curves of the Fibro-Stiffness index for prediction of F≥2 (0.90), F≥ 3 (0.90) and F= 4(0.92) in the estimation group and those for F≥ 3 (0.93) and F =4 (0.97) in the validation group were the highest among the 5 methods examined. The accuracy of the Fibro-Stiffness index had highest values for F≥2, F≥3 and F=4 in both the estimation and validation groups. The diagnostic performance for F= 4 was improved by a combination of the Fibro-Stiffness index with serum hyaluronic acid level. CONCLUSION: The Fibro-Stiffness index was constructed and validated. It showed superior diagnostic performance to other indices for F ≥ 2,3 and 4.Naohiro Ichino Keisuke Osakabe Toru Nishikawa Hiroko Sugiyama Miho Kato Shiho Kitahara Senju Hashimoto Naoto Kawabe Masao Harata Yoshifumi Nitta Michihito Murao Takuji Nakano Yuko Arima Hiroaki Shimazaki Koji Suzuki Kentaro Yoshioka 2010World Journal of Gastroenterology2010,16,38:7
4Use of color Doppler ultrasonography in the diagnosis of anomalous connection in pancreatobiliary disease显示文摘AIM: To estimate the detectability of anomalous connection in pancreatobiliary disease (ACPBD) cases, measuring gallbladder wall blood flow (GWBF).METHODS: In the retrospective study, we enrolled 42subjects with gallbladder wall thickening. GWBF velocity was determined as an average value of the peak velocity of color signals on the gallbladder wall, three times in each case. Based on the findings on endoscopic ultrasonography (EUS) or endoscopic retrograde cholangiopancreatography (ERCP), the 42 subjects were divided into 11 cases with ACPBD and 31 cases without ACPBD. In the prospective study, the subjects were 92 cases with gallbladder wall thickening. Using the cut-off level of the flow velocity obtained in the retrospective study, the usefulness of measuring GWBF velocity in diagnosing ACPBD was evaluated.RESULTS: In the retrospective study, imaging of GWBF was obtained in 40 of the 42 subjects. The mean GWBF velocity of the ACPBD cases was 29.4±3.9 cm/s(mean±SD), which was significantly different (P<0.0001;95% CI 5.48-13.2) from that of the without ACPBD cases(20.1±5.9 cm/s). Based on this result, we prepared a receiver operating characteristic curve, and the cut-off level appropriate for diagnosing ACPBD was estimated to be 25 cm/s. In the prospective study, GWBF was detected in 86 of the 92 subjects. Based on the EUS or ERCP findings, the 92 subjects were divided into 15 cases with ACPBD and 77 cases without ACPBD. When a cut-off level of 25 cm/s was employed, ACPBD could be diagnosed with a sensitivity of 87.0% (13/15) and a specificity of87.3% (62/71).CONCLUSION: Measurement of GWBF velocity, which is less invasive and provides objective values, is very useful for diagnosing ACPBD prior to the development of malignant tumors in cases with gallbladder wall thickening.Hiroki Kawashima Yoshiki Hirooka Akihiro Itoh Senju Hashimoto Terutomo Itoh Kazuo Hara Akira Kanamori Naoki Ohmiya Yasumasa Niwa Hidemi Goto 2005World Journal of Gastroenterology2005,11,7:7
5Bisphenol A in combination with TNF-a selectively induces Th2 cell-promoting dendritic cells in vitro with an estrogen-like activity显示文摘Bisphenol A(BPA)is a monomer used in manufacturing a wide range of chemical products,including epoxy resins and polycarbonate.BPA,an important endocrine disrupting chemical that exerts estrogen-like activities,is detectable at nanomolar levels in human serum worldwide.The pregnancy associated doses of 17b-estradiol(E2)plus tumor-necrosis factor-a(TNF-a)induce distorted maturation of human dendritic cells(DCs)that result in an increased capacity to induce T helper(Th)2 responses.The current study demonstrated that the presence of BPA during DC maturation influences the function of human DCs,thereby polarizing the subsequent Th response.In the presence of TNF-a,BPA treatment enhanced the expression of CC chemokine ligand 1(CCL1)in DCs.In addition,DCs exposed to BPA/TNF-a produced higher levels of IL-10 relative to those of IL-12p70 on CD40 ligation,and preferentially induced Th2 deviation.BPA exerts the same effect with E2 at the same dose(0.01–0.1 mM)with regard to DC-mediated Th2 polarization.These findings imply that DCs exposed to BPA will provide one of the initial signals driving the development and perpetuation of Th2-dominated immune response in allergic reactions.Hongchuan Guo Tianyi Liu Yasushi Uemura Shunchang Jiao Deqing Wang Zilin Lin Yayoi Narita Motoharu Suzuki Narumi Hirosawa Yasuko Ichihara Osamu Ishihara Hirosato Kikuchi Yasushi Sakamoto Satoru Senju Qiuhang Zhang Feng Ling 2010Cellular & Molecular Immunology2010,7,3:6
6Usefulness of a novel oncofetal antigen,glypican-3,for diagnosis and immunotherapy of hepatocellular carcinoma显示文摘Nishimura Y Nakatsura T Senju S 0,,05:1
7Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker显示文摘Nakatsura T Yoshitake Y Senju S 2003Biochem and Biophy Res Communication2003,306,:1
8Glypican-3, overexpressed Specifically in human hepatocellular carcinoma, is a novel tumor marker显示文摘Nakatsura T Yoshitake Y Senju S 2003Biochem Biophys Res Commun2003,306,:1
9Preparation of polyvinylamine by Hofmann degradation of polyaerylamide 显示文摘Tanak H Senju R 1976Bull Chem Soc Jpn1976,49,10:1
10Hofmann degradation of polyacrylamide 显示文摘Tannaka H Senju R 1976Kobunshi Ronbunshu1976,33,6:1
11Glypican-3 overpressed specifically in human hepatocellular carcinoma,is a novel tumor marker显示文摘Nakastura T Yoshitake Y Senju S 2003Biochem Biophys Res Commun2003,306,3:1
12Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells显示文摘Senju S Hirata S Matsuyoshi H 2003Blood2003,101,9:1
13Cellular and humoral iune responses to a human pancreatic cancer antigen,coactosin-like protein,originally defined by the SEREX method显示文摘Nakatsura T Senju S Ito M 2002Eur J Iunol2002,32,3:1
14Identification of SPARC as a candidate target antigen for immunotherapy of various cancers显示文摘Inoue M Senju S Hirata S 2010Int J Cancer2010,127,6:1
15Amino acid substitu- tions in mosaic penicillin-binding protein 2 associated with re- duced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae 显示文摘Takahata S Senju N Osaki Y 2006Antimicrob Agents Chemother2006,50,11:1
16Preparation of polyvinlamine by the Hofmann degradation of polyacrylamide 显示文摘TANAKA Hiroo SENJU Ryoichi 1976Bulletin of The Chemical Society of Japan1976,49,10:1
17Glypican - 3, overexpressed specifically in human hepatocellular carcinoma,is a novel tumor marker 显示文摘Nakatsura T Yoshitake Y Senju S 2003Biochem Biophys Res Commun2003,306,1:1
18Active Pro- cessing of Biological Motion Perception: An ERP Study显示文摘Hirai M Senju A Fukushima H 2005Cognitive Brain Research2005,23,23:1
19Glypican-3,overexpressed specifically in human hepatocellular carcinoma,is a novel tumor marker显示文摘 Yoshitake Y Senju S 2003Biochem Biophys Res Commun2003,306,:1
20Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein:application to antitamor vaccination显示文摘MATSUYOSH HI SENJU S HIRATA S 2004J Immunol2004,172,:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费